Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
76 participants
INTERVENTIONAL
2018-02-20
2022-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
As an add-on, the investigators will examine COVID-associated changes in substance use and whether participants in the memory updating groups might be more resilient to these effects. It is predicted that the changes in substance use will depend on whether the substances are used primarily in social settings.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Stress-management and Biofeedback on Craving in Smoking Abstinence: A Pilot Study
NCT01080092
Cognitive and Affective Mechanisms Underlying an Olfactory Approach to Modify Cigarette Craving
NCT04902469
Nicotine Withdrawal and Reward Processing: Connecting Neurobiology to Real-world Behavior
NCT03840694
Effects of Smoking Environment on Craving and Smoking
NCT02416986
Environments as Smoking Cues: Imaging Brain Substrates, Developing New Treatments (CameraCue)
NCT01840111
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
COVID-associated changes in substance use will be quantified over three telephone interviews: one at the end of March / beginning of April 2020 (at the start of the pandemic), one at the end of April / beginning of May, and a final one which will be instituted if feasible once the infection rates and social distancing policies have decreased.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Stress task and smoking cue
Exposure to a psychosocial stress task followed by smoking video cues
Stress induction
Exposure to a psychosocial stressor
Cue induction
Exposure to a smoking-related task
Stress task and neutral cue
Exposure to a psychosocial stress task followed by neutral video cues
Stress induction
Exposure to a psychosocial stressor
Neutral cue exposure
Exposure to neutral cues
Control task and smoking cue
Exposure to a control task followed by smoking video cues
Control stress exposure
Exposure to a control task (no stress)
Cue induction
Exposure to a smoking-related task
Control task and neutral cue
Exposure to a control task followed by neutral video cues
Control stress exposure
Exposure to a control task (no stress)
Neutral cue exposure
Exposure to neutral cues
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Stress induction
Exposure to a psychosocial stressor
Control stress exposure
Exposure to a control task (no stress)
Cue induction
Exposure to a smoking-related task
Neutral cue exposure
Exposure to neutral cues
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Willingness to abstain from smoking for 4 hours prior to each laboratory visit
Exclusion Criteria
* Endocrinological problems
* Significant mental or physical health conditions
* Pregnancy
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Marco Leyton
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marco Leyton
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marco Leyton, PhD
Role: PRINCIPAL_INVESTIGATOR
McGill University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
McGill University
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Barnabe A, Gamache K, de Camargo JVP, Allen-Flanagan E, Rioux M, Pruessner J, Leyton M, Nader K. A novel stress-based intervention reduces cigarette use in non-treatment seeking smokers. Neuropsychopharmacology. 2023 Jan;48(2):308-316. doi: 10.1038/s41386-022-01455-6. Epub 2022 Sep 29.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
421-0318
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.